Precigen, Inc. (PGEN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.8200 |
| Open | 1.8000 |
| Bid | 1.8100 x 3000 |
| Ask | 1.8500 x 2200 |
| Day's Range | 1.7600 - 1.8800 |
| 52 Week Range | 1.1200 - 2.9000 |
| Volume | |
| Avg. Volume | 1,415,335 |
| Market Cap | 459.343M |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4720 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.28 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PGEN
Related Research
- Precigen, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.RatingFair ValueEconomic MoatyesterdayMorningstar
- American City Business Journals
Germantown's Precigen raises $75M to advance treatments for rare diseases
The clinical-stage company is developing gene and cell therapies for cancers, autoimmune disorders and infectious diseases.
- PR Newswire
Precigen Announces Closing of Public Offering of Common Stock
Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Gross proceeds to Precigen from the offering were approximately $75.0 million before deducting the underwriting discount and other offering expenses payable by Precigen.
- PR Newswire
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 6,428,571 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75.0 million, excluding any exerc
